Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Duodenal Neoplasms 1Colorectal Neoplasms 1Barrett Esophagus 1Attenuated familial adenomatous polyposis 1Adenomatous Polyposis Coli 1Adenocarcinoma Of Esophagus 1

Interventions

Bevacizumab 32Cetuximab 28Fluorouracil 26Leucovorin 24Specimen Handling 23Oxaliplatin 23pembrolizumab 18Biopsy 16Magnetic Resonance Spectroscopy 14Irinotecan 13Nivolumab 9atezolizumab 7Folfox protocol 7fludarabine 6balstilimab 6Pemetrexed 6Panitumumab 6Cyclophosphamide 6Cisplatin 6Carboplatin 6Capecitabine 6trifluridine tipiracil drug combination 5encorafenib 5Standard of Care 5IFL protocol 5HMPL-013 5Gemcitabine 5dehydroftorafur 4Immunoglobulin G 4Disulfides 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Colorectal Neoplasms × obeticholic acid × 30 days × Clear all
NCT05223036 2026-05-14

Testing Obeticholic Acid for Familial Adenomatous Polyposis

National Cancer Institute (NCI)

Phase 2 Terminated
15 enrolled
Gastrointestinal

Attenuated familial adenomatous polyposis, Duodenal Neoplasms, Adenomatous Polyposis Coli, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡